Compare Nextpower Inc. Common Stock (NXT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nextpower Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Nextpower Inc. Common Stock trades at $80.96 (market cap $12.53B), while State Street SPDR S&P Biotech ETF trades at $148.72 (market cap $10.05B). The key difference: Nextpower Inc. Common Stock is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nextpower Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| NXT | XBI | |
|---|---|---|
Market Cap | $12.53B | $10.05B |
Volume | 3,195,746 | 10,367,649 |
Sector | Energy | Broad Market / Factor |
52-Week High | $156.40 | $169.55 |
52-Week Low | $77.93 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $11.98B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
XBI trades at $150.00, up 2.18% today, but faces a bearish technical signal with moving averages indicating selling pressure. Analyst consensus is neutral with 100% hold ratings. Recent news highlights biotech sector optimism from cancer vaccine breakthroughs and M&A activity, though the ETF's 0.35% expense ratio is higher than some peers.
Outlook is mixed: positive catalysts from drug development and sector momentum exist, but high volatility and lack of fundamental valuation metrics pose risks. The current price near resistance at $150 suggests near-term consolidation is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
